Related Experiment Video

Updated: Dec 27, 2025

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.3K

Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma

Haoyu Wang1,2,3,4, Zhaohui Wang1,2,3, Huiping Zhang1,2,3

  • 1Division of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.

Molecular Oncology
|February 29, 2020
PubMed

Insights

A novel bispecific immunotoxin targeting CC chemokine receptor 4 (CCR4) and CD25 shows promise for treating cutaneous T-cell lymphomas (CTCL). This therapy is more effective than existing treatments for refractory and recurrent CTCL.

Area of Science:

  • Oncology
  • Immunology
  • Drug Development

Background:

  • Cutaneous T-cell lymphomas (CTCL) often express cell-surface markers CC chemokine receptor 4 (CCR4) and CD25.
  • Existing targeted therapies include IL2 fusion toxin and anti-human CCR4 immunotoxin (CCR4 IT).

Purpose of the Study:

  • To compare the efficacy of CCR4 IT versus IL2 fusion toxin for targeting CD25+ CCR4+ CTCL.
  • To develop and evaluate a novel IL2-CCR4 bispecific immunotoxin for CTCL treatment.

Main Methods:

  • Development of diphtheria toxin-based IL2 fusion toxin and CCR4 IT.
  • Construction and in vitro/in vivo testing of an IL2-CCR4 bispecific immunotoxin.
  • Comparative efficacy studies of individual and bispecific immunotoxins against CD25+ CCR4+ CTCL models.

Main Results:

  • CCR4 IT demonstrated greater efficacy than IL2 fusion toxin in targeting CD25+ CCR4+ CTCL.
  • The novel IL2-CCR4 bispecific immunotoxin showed significantly enhanced effectiveness compared to either monotherapy.
  • The bispecific immunotoxin proved superior to IL2 fusion toxin and CCR4 IT alone.

Conclusions:

  • CCR4 IT is a more effective targeted therapy than IL2 fusion toxin for specific CTCL subtypes.
  • The IL2-CCR4 bispecific immunotoxin represents a promising novel therapeutic candidate.
  • This bispecific immunotoxin offers potential for treating refractory and recurrent CD25+ and/or CCR4+ CTCL.
Keywords:
CCR4IL2Ontak®cutaneous T-cell lymphomaimmunotoxin

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K